Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Monday, 2 October 2017

Shire plc : Total voting rights

Shire plc    

Published: 15:00 CEST 02-10-2017 /GlobeNewswire /Source: Shire plc / : SHP /ISIN: JE00B2QKY057

Shire plc : Total voting rights

Total Voting Rights


October 2, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority's (the "FCA") Disclosure Guidance and Transparency Rules, notifies the market of the following:


As at September 30, 2017, the Company's issued ordinary share capital comprised 908,509,840 ordinary shares of 5 pence each with voting rights and a further 7,357,283 ordinary shares held in treasury.


Therefore, the total number of voting rights in the Company is 908,509,840. This is the figure which should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.



Sarah Rixon

Company Secretarial Assistant



For further information please contact:


Investor Relations



Ian Karp


+1 781 482 9018

Robert Coates


+44 1256 894874




Lisa Adler


+1 617 588 8607





About Shire


Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.


Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Shire plc, 1 Kingdom Street Paddington, London W2 6BD, United Kingdom
If you would like to unsubscribe and stop receiving these e-mails click here.